NuSep licences gels
Wednesday, 17 September, 2008
NuSep [ASX: NSP] will accept an offer to license its electrophoresis gel business.
The third party had offered to acquire NuSep's gels business outright or to license the technology.
It was decided that licensing the technology would provide the best return for shareholders, the company said.
The licensing deal should give NuSep enough money to fund this commercialisation of its MF10 and SpermSep separation instruments without any additional fund-raising, and will likely generate an ongoing royalty fee.
NuSep also supplies research grade biological products such as human IgG and albumin.
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
